Novelion Therapeutics Inc. announced unaudited consolidated financial results for the quarter and six months ended June 30, 2017. For the quarter, the company reported net revenues of CAD 40,877,000. Loss from operations was CAD 11,772,000 against CAD 7,403,000 for the same period a year ago. Loss before provision for income taxes was CAD 21,310,000 against CAD 5,115,000 for the same period a year ago. Net loss was CAD 21,436,000 against CAD 5,120,000 for the same period a year ago. Basic and diluted net loss per common share was CAD 1.15 per share against CAD 0.48 per share for the same period a year ago. Non-GAAP net loss was CAD 1,396,000 against CAD 26,408,000 for the same period a year ago. Non-GAAP basic net loss per common share was CAD 0.08 per share against CAD 2.50 per share for the same period a year ago. Non-GAAP net revenues were CAD 40,877,000 against CAD 44,530,000 for the same period a year ago.

For the six months, the company reported net revenues of CAD 70,861,000. Loss from operations was CAD 33,435,000 against CAD 16,329,000 for the same period a year ago. Loss before provision for income taxes was CAD 52,133,000 against CAD 27,003,000 for the same period a year ago. Net loss was CAD 52,398,000 against CAD 27,014,000 for the same period a year ago. Basic and diluted net loss per common share was CAD 2.82 per share against CAD 2.56 per share for the same period a year ago. Non-GAAP net loss was CAD 10,083,000 against CAD 97,403,000 for the same period a year ago. Non-GAAP basic net loss per common share was CAD 0.54 per share against CAD 9.22 per share for the same period a year ago. Non-GAAP net revenues were CAD 70,861,000 against CAD 80,246,000 for the same period a year ago.

For the full year 2017, the company expects total net revenues between CAD 135 million and CAD 145 million, compared to the prior range of between CAD 155 million and CAD 165 million.